6 ï <1

(Se 2552)

30, 2020

D 0301,

52

A 24 , DA 0302. 2 ( 2D•)

C

C 0110,

2D

C 0111, D -4

C 0112, -2

D 24 2020 A

D A 80

C B949.6 30, 2020.

C 30, 2020
B180.5 B112.3


B54.3
32.6% B112.3
30, 2020, 30, 2019.

B62.0 26.3%
B173.5 30, 2020,
30, 2019.

B61.8 26.3% B173.7
30, 2020, 30, 2019.

| Trial # | Drugs | Disease indication | Study type | Pre-clinical | Phase I | Phase II | Phase III | NDA |
|---|---|---|---|---|---|---|---|---|
| HMM0301 | Dorzagliatin | Drug naïve T2D | Registration trial | | | | | |
| HMM0302 | Dorzagliatin & metformin | Metformin tolerated T2D | Registration trial | | | | | |
| HMM0311 | Dorzagliatin +/vs OAD | Metformin tolerated T2D | Label expansion | | | | | |
| HMM0312 | Dorzagliatin +/vs OAD | Metformin tolerated T2D | Label expansion | | | | | |
| HMM0109 | Dorzagliatin | Hepatic impaired T2D | Label expansion | | | | | |
| HMM0110 | Dorzagliatin | Renal impaired T2D | Label expansion | | | | | |
| HMM0111 | Dorzagliatin + DPP-4 | | | | | | | |

C[illegible]A1[illegible]52[illegible]



(N=150)
8.35
(N=307)
7.20
(N=245)
7.18
(N=284)
6.95
(N=105)
HbA1c level by visit (%)
8.00
7.50
7.00
6.50
6.00
0
4w
8w
12w
16w
20w
24w
Double-Blind Treatment
Open-label Treatment
Dorzagliatin
Placebo

*Figure*


A [illegible] 2D [illegible] H444_0110, H444_0111, H444_0112 [illegible] H444_0301 [illegible]


1, 2020, DA 0302. DA 0302

2D









[illegible]

[illegible] 30, 2020 [illegible] B0.1 [illegible] B2.2 [illegible] 30, 2019, [illegible] 2019.

[illegible]

[illegible]

| | [illegible]30, | | | |
|---|---|---|---|---|
| | 2020 | % | 2019 | % |
| | [illegible] '000 | | [illegible] '000 | |
| D [illegible] C | 46,565 | 41 % | 85,342 | 51 % |
| D [illegible] | 225 | 0 % | 308 | 0 % |
| C [illegible] C | 4,652 | 4 % | 17,966 | 11 % |
| C | 55,261 | 50 % | 54,297 | 33 % |
| D [illegible] | 1,272 | 1 % | 2,018 | 1 % |
| | 4,278 | 4 % | 6,572 | 4 % |
| | 112,253 | 100.0 % | 166,503 | 100.0 % |

[illegible] B54.3 [illegible] B112.3 [illegible] 30, 2020 [illegible] B166.5 [illegible] 30, 2019.

[illegible]

[illegible] B38.8 [illegible] [illegible] 52-[illegible]

D[illegible]0301 [illegible] 2020 [illegible]

DA [illegible]0302 [illegible] D [illegible] 2018;

[illegible] B13.3 [illegible]

**Notes**

[illegible] B167.4 [illegible] 30, 2020. A [illegible] 30, 2020, [illegible] B949.6 [illegible].

A [illegible] 30, 2020, [illegible] C [illegible].

**6 [illegible]**

[illegible]:

| | [illegible]30, | |
|---|---|---|
| | 2020 | 2019 |
| | ’000 | ’000 |
| &D [illegible] | 91,247 | 145,572 |
| A [illegible] | | |
| [illegible] | 27,386 | 20,126 |
| [illegible] | 48,772 | 32,456 |
| | 76,158 | 52,582 |
| | 167,405 | 198,154 |

**6 [illegible]**

[illegible] 30, 2019 [illegible] 2020:

| | [illegible]30, | |
|---|---|---|
| | 2020 | 2019 |
| | ’000 | ’000 |
| [illegible] | (167,405) | (198,154) |
| [illegible] ( [illegible] ) | 2,871 | (1,666) |
| [illegible] ( [illegible] ) | (3,832) | 409 |
| [illegible] | 12,350 | 2,490 |
| [illegible] | (156,016) | (196,921) |

[illegible]

[illegible]

D[illegible] 30, 2020, [illegible] B167.4 [illegible] B173.5 [illegible] B29.2 [illegible] B23.1 [illegible] 30, 2020 [illegible]

D[illegible] 30, 2019, [illegible] B198.2 [illegible] B235.5 [illegible] B40.0 [illegible] B2.7 [illegible] 30, 2019 [illegible]

[illegible]

[illegible] B2.9 [illegible] 30, 2020, [illegible] B1.7 [illegible] 30, 2019, [illegible]

[illegible]

[illegible] B3.8 [illegible] 30, 2020, [illegible] B0.4 [illegible] 30, 2019, [illegible]

[illegible]

[illegible] B1,011.70 [illegible] D[illegible] 31, 2019 [illegible] B868.5 [illegible] 30, 2020. C[illegible] [illegible] B1,120.5 [illegible] D[illegible] 31, 2019 [illegible] B961.6 [illegible] 30, 2020, [illegible] B1,105.6 [illegible] D[illegible] 31, 2019 [illegible] B949.6 [illegible] 30, 2020, [illegible] 30, 2020.

[illegible]

[illegible] A [illegible] C [illegible]

A [illegible] B ([illegible] A B). [illegible] A [illegible] 16 [illegible] C [illegible] -19- [illegible] C [illegible].

[illegible]

A [illegible] 30, 2020, [illegible] B87.5 [illegible] :

| | [illegible] 30, 2020 ₦'000 | [illegible] 31, 2019 ₦'000 |
|---|---|---|
| C[illegible] | 14,822 | 12,019 |
| [illegible] | 72,652 | 77,959 |
| | 87,474 | 89,978 |

[illegible] 30, 2020 [illegible]. A [illegible] 30, 2020, [illegible].

[illegible]

[illegible]


[illegible] C [illegible]

A [illegible] B C,


C [illegible]


[illegible]

C [illegible],



| | As at 30, 2020 | As at 31, 2019 |
|---|---|---|
| | '000 | '000 |
| | $ (29,140) | (42,433) |
| | $ (2,330) | (2,634) |





| | | | |
|---|---|---|---|
| | | 2020 | 2019 |
| | | ’000 | ’000 |
| | | | |
| | 3 | 3,554 | 3,379 |
| | | 3,463 | 1,995 |
| A | | (65,972) | (74,242) |
| | | (2,247) | (129) |
| | | (112,253) | (166,503) |
| | 4 | (173,455) | (235,500) |
| | 5 | | |
| | | (173,455) | (235,500) |
| | | | |
| | | (202) | |
| | | (173,657) | (235,500) |
| | | | |
| | | (173,657) | (235,500) |
| | | (173,657) | (235,500) |

30, 2020

1.

C C
10, 2009 14, 2018.
B 309, C 1-1104, C
C 275 A, D, 201203, C.

C
5552, 2D.

2.

A 34 ( A 34) A
B A 16
( )

C B,

3.

| | 30, 2020 | |
|---|---|---|
| | 2020 ' 000 | 2019 ' 000 |
| B ( ) | 3,167 | 3,337 |
| | 327 | 42 |
| | 60 | |
| | 3,554 | 3,379 |

:

4. [illegible]

[illegible]:

| | [illegible]30, 2020 '000 | 2019 '000 |
|---|---|---|
| D[illegible] | 2,277 | 1,504 |
| D[illegible] | 10,106 | 2,135 |
| A[illegible] | 137 | 85 |
| [illegible]): | | |
| [illegible] | 60,624 | 56,124 |
| [illegible] | 1,657 | 2,687 |
| [illegible] | 30,216 | 42,046 |
| | 92,497 | 100,857 |
| A[illegible] | 680 | 680 |
| [illegible] | 785 | 1,620 |

[illegible]:

C -19. A A (2020) .11, C D-19 2020.

5. [illegible]

C C C

C ( •) C 25 % C C

D[illegible]

6. [illegible]

D 2011, C ( A A •) A ( •) C ( •). A A C $2.0 2012.

2017, C $1.0 C ( )

C $4.0
C ( ) $33.0
C ( ).
C $15.0
$500.0 $40.0
$1.0
C

7.

C
:

:

| | 30, | |
|---|---|---|
| | 2020 | 2019 |
| | ' 000 | ' 000 |
| | ( | ( |
| C | (173,455) | (235,500) |

:

| | 30, | |
|---|---|---|
| | 2020 | 2019 |
| | ( | ( |
| | 948,878,897 | 939,507,659 |

30, 2020 2019
C .

30, 2020 2019

8.

D 30, 2020, B1,498,000 ( ) ( 30, 2019: B4,359,000 ( )) 30, 2020 B10,209,000 ( ) (D 31, 2019: B10,988,000 ( )).

9.

| | As at 30, 2020 | As at 31, 2019 |
|---|---|---|
| | HK$'000 | HK$'000 |
| | 1,986 | 2,838 |
| | 1,832 | 1,462 |
| | 3,504 | 4,117 |
| | 31,270 | 26,248 |
| | 8,159 | 10,552 |
| | 339 | 342 |
| | 47,090 | 45,559 |
| | 11,977 | 14,852 |
| | 35,113 | 30,707 |
| | 47,090 | 45,559 |

10.

0.001 % 1.2 % 30, 2020 (D 31, 2019: 0.05 % 2.80 % ).

11.

| | As at 30, 2020 | As at 31, 2019 |
|---|---|---|
| | HK$'000 | HK$'000 |
| | 46,685 | 47,941 |
| | 16,004 | 28,577 |
| | 4,132 | 3,660 |
| | 1,857 | 6,662 |
| | 1,065 | 1,477 |
| | 69,743 | 88,317 |

30

| | | | |
|---|---|---|---|
| | | As at December 30, 2020 RM'000 (Audited) | As at December 31, 2019 RM'000 (Audited) |
| | 30 | 46,685 | 47,491 |
| | | 46,685 | 47,491 |

12.

C

13.

30, 2020

C C C A 14
C C
C D .

B C
C C 30, 2020. B
B .

A C
D . C 25, 2020.

A D
C 大唐西市絲路投資控股有限公司 ( C : 620)
29 2020.

D 13.51B .

30, 2020 , D
2410
A • ( 2410•) .
C A .

C
C 30, 2020,
.

2020
( ) C ( ). C
30, 2020
C
C .

2019 C A 22, 2020.

C :

| Type | Date | Tranche | Number of Shares Underlying Options | Weighted Average Exercise Price |
|---|---|---|---|---|
| Grant: Director | | | | |
| D C | Exercisable on | | | |
| | A : 25, 2019 | 1 | 12,079,000 | $8.89 |
| C | Exercisable on | | | |
| C | A : 17, 2019 | 1 | 300,000 | $8.89 |
| Grant: Employee | | | | |
| | Exercisable on | | | |
| | A : 29, 2018 | 2 | 75,000 | $6.81 |
| | A 26, 2018 | 3 | 500,000 | $8.17 |
| | A : D 31, 2018 | 4 | 500,000 | $8.06 |
| | A : 15, 2019 | 1 | 8,540,300 | $8.89 |
| | A : 19, 2019 | 5 | 500,000 | $6.80 |
| Grant: Consultant | | | | |
| | Exercisable on | | | |
| | A : 15, 2019 | 1 | 200,000 | $8.89 |

(1) 8, 2019 23, 2019 11, 2019 75 % 36 $8.866.

(2) 29, 2018 29, 2018 75 % 36 $7.192.

(3) 26, 2018 26, 2018 75 % 36 $7.970.

(4) D. 31, 2018 D. 31, 2018 75 % 36 $8.30.

(5) A 29,2019 19, 2019 75 % 36 $6.80.



( )• ( ) C $0.001

$• A

A

B B

C

D

, A 17, 2020

A C D C C C C D C C A C